drugset / Trial / NCT03641352
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.
Timeline
- Start
- 2018-05-02
- Primary completion
- 2021-04-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lobeglitazone | Small molecule | 0.5 mg | Oral |